← Leaderboards
Ladislau Christopher Kovari
Emory University
$3,522,884
Attributed
$7,233,701
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,233,701 · 4
By mechanism
R01$6,835,826 · 3
R21$397,875 · 1
Top collaborators
- Raymond F. Schinazi8 shared
- Elizabeth Ann Fitzpatrick5 shared
Most similar at Emory University
Same institution · by research overlap
- Raymond F. Schinazi$18,319,973
- Stefan G Sarafianos$26,943,765
- Daniel Kalman$11,539,324
- Kira Newman$251,629
- Asuncion Mejias$2,044,603
Others in their field
Top investigators on “Protease Inhibitor”
- Constance Ann Benson · University Of California, San Diego$150,461,206
- Robert Turner Schooley · University Of Colorado Denver$48,400,257
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,777,114
- Daniel R Kuritzkes · Brigham And Women'S Hospital$26,572,064
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester$24,364,826
Research focus
Protease InhibitorDrug ResistanceNanomolarEnzymesLigandsMolecular ModelingDrug CandidateCytotoxicityEfficacy TestingEnterovirusLeadLibrariesLiver MicrosomesCoronavirusCellsNorovirusDesignBiological AvailabilityAnalogAqueousCharacteristicsBindingInvestigational New Drug ApplicationNucleoside Analog
Grant awards (13)
Anti-norovirus protease inhibitors for immunocompromised patients$1,504,695
R01 · FY2025 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$642,901
R01 · FY2025 · AI
Anti-norovirus protease inhibitors for immunocompromised patients$762,258
R01 · FY2024 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$645,603
R01 · FY2024 · AI
Anti-norovirus protease inhibitors for immunocompromised patients$796,178
R01 · FY2023 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$648,225
R01 · FY2023 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$650,769
R01 · FY2022 · AI
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$681,379
R01 · FY2021 · AI
PROTEASE INHIBITOR DESIGN AGAINST MDR HIV VARIANTS$177,826
R21 · FY2006 · AI · contact PI
PROTEASE INHIBITOR DESIGN AGAINST MDR HIV VARIANTS$220,049
R21 · FY2005 · AI
STRUCTURE-FUNCTION STUDY OF HIV PROTEASE DRUG RESISTANCE$144,229
R01 · FY2002 · GM
STRUCTURE-FUNCTION STUDY OF HIV PROTEASE DRUG RESISTANCE$181,582
R01 · FY2001 · GM
STRUCTURE-FUNCTION STUDY OF HIV PROTEASE DRUG RESISTANCE$178,007
R01 · FY2000 · GM